Banco Bilbao Vizcaya Argentaria S.A. Boosts Vertex Pharmaceuticals Stake

Spanish banking giant increases holding in biotech firm by 4.8% in Q3

Mar. 15, 2026 at 8:22am

Got story updates? Submit your updates here. ›

Banco Bilbao Vizcaya Argentaria S.A. (BBVA), a major Spanish financial group, increased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.8% in the third quarter of 2025, according to a recent SEC filing. BBVA now owns 98,153 shares of the Boston-based biotech company, worth approximately $38.4 million.

Why it matters

Vertex Pharmaceuticals is a leading biotechnology firm focused on developing treatments for serious diseases, particularly cystic fibrosis. The increase in BBVA's stake suggests the Spanish bank sees long-term growth potential in Vertex's pipeline and commercial products.

The details

According to the 13F filing, BBVA purchased an additional 4,464 shares of Vertex Pharmaceuticals during the third quarter. This brings the bank's total holding in the biotech firm to 98,153 shares. Vertex Pharmaceuticals is known for its portfolio of small-molecule CFTR modulators that target the underlying cause of cystic fibrosis.

  • BBVA increased its Vertex Pharmaceuticals stake in the 3rd quarter of 2025.

The players

Banco Bilbao Vizcaya Argentaria S.A. (BBVA)

A major Spanish financial group and one of the largest banks in Europe.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

A Boston-based biotechnology company focused on developing treatments for serious diseases, particularly cystic fibrosis.

Got photos? Submit your photos here. ›

The takeaway

BBVA's increased stake in Vertex Pharmaceuticals underscores the Spanish bank's confidence in the biotech firm's long-term growth prospects, particularly its leading position in the cystic fibrosis treatment market.